LOGIN  |  REGISTER

Cassava Sciences Mourns the Death of Board Member Sanford “Sandy” Robertson

August 05, 2024 | Last Trade: US$2.93 0.42 -12.54

AUSTIN, Texas, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today reflected on the passing of long-time board member Sanford Robertson.

We are profoundly saddened by the passing of our dear friend and colleague, Sandy Robertson. Sandy served on the Board of Directors of Cassava Sciences since its inception as a public company in 1998. Sandy's commitment to Cassava’s mission and success was unwavering. Sandy’s success in the business world is well recognized by the hundreds of companies that he helped build and the entrepreneurs who created those companies. Everyone who knew or worked alongside Sandy understood his powerful intelligence as well as his remarkable kindness. His success in business was legendary but what those who knew him will remember was who he was: Sandy was the personification of someone who would treat others as he would like to be treated. We will miss him terribly as will anyone who knew him.

About Cassava Sciences, Inc.

Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer’s disease. For more information, please visit: https://www.CassavaSciences.com  

For More Information Contact:
Eric Schoen, Chief Financial Officer
(512) 501-2450, or This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB